Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update

Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company....

Related Keywords

Germany ,Norway ,Oslo ,Spain ,Belgium ,Australia ,United Kingdom ,Norwegian ,Hans Vassg ,Joachim Midttun ,European Medicines Agency ,Euronext Oslo Stock Exchange ,Drug Administration ,Fast Track ,Orphan Drug ,Carlos De Sousa ,European Journal ,Norwegian Securities Trading ,Financial Manager ,Markets ,